Liver cancer cell proliferation

Liver cancer cell proliferation is a pathological biological process characterized by the rapid and uncontrolled division of malignant cells within the liver, primarily hepatocytes in the case of hepatocellular carcinoma (HCC) (Llovet et al., Nature Reviews Disease Primers, 2021). This process is driven by the dysregulation of multiple signaling pathways, such as the Wnt/beta-catenin, PI3K/Akt/mTOR, and MAPK/ERK pathways, which bypass normal cell cycle checkpoints (National Cancer Institute, 2023). It is important to note that 'Liver cancer cell proliferation' is a phenotypic outcome or a disease state rather than a specific molecular target like a receptor or enzyme. While therapeutic agents are designed to inhibit this process, they do so by targeting specific proteins—such as the multi-kinase inhibitors sorafenib and lenvatinib—rather than the process itself directly (PubMed, PMC7460613). In clinical practice, the rate of proliferation is often monitored through biomarkers like Alpha-fetoprotein (AFP) or the nuclear protein Ki-67, which serve as indicators of tumor aggressiveness and treatment response (StatPearls, 2023). Consequently, while this process is central to oncology, it does not meet the criteria for a singular therapeutic target entity.

Other names

Hepatocellular carcinoma proliferationHepatic malignancy growthHCC cell division

Not applicable as this is a biological process, not a specific molecular target.